Lidocaine injection before surgery for oropharyngeal cancer
Official title: A Phase I Randomized Controlled Trial of Intratumoral Lidocaine Injection Before Transoral Robotic Surgery (TORS) and Neck Dissection for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Run by Abramson Cancer Center at Penn Medicine · NCT06747390 · Data updated 2026-11-12
This study tests if giving a lidocaine injection before surgery can help improve outcomes for patients with oropharyngeal cancer.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | April 23, 2025 |
| Main results expected | November 1, 2026 |
| Study ends | November 1, 2028 |
| Registry record updated | May 12, 2026 |
| Trial ID | NCT06747390 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with histologically confirmed oropharyngeal squamous cell carcinoma who are scheduled for direct laryngoscopy and TORS.
✕Probably not a fit
Patients who have received prior radiation or chemotherapy for head and neck cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase I trial evaluates the safety and efficacy of intratumoral lidocaine injection in patients with oropharyngeal squamous cell carcinoma undergoing TransOral Robotic Surgery (TORS). Participants will be randomly assigned to receive either a lidocaine injection or no injection during direct laryngoscopy prior to surgery. The study aims to assess the impact of lidocaine on tumor response and various survival metrics, including locoregional control and overall survival. Blood samples will be collected to analyze potential biological effects of the treatment.
Why it matters
Potential benefit: If successful, this approach could enhance tumor response and improve survival outcomes for patients with oropharyngeal cancer.
How similar studies have gone: While the use of lidocaine in this context is novel, similar studies exploring local anesthetics for anticancer effects have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients 18 years older or more. Histologically confirmed diagnosis of squamous cell carcinoma of the oropharynx or neck. Clinical T1, T2, T3, or T4 stage disease of the oropharynx (per AJCC 8th Ed). Any clinical N stage disease (per AJCC 8th Ed). Patients must be undergoing direct laryngoscopy +/- biopsy at the University of Pennsylvania as part of their work-up for consideration of definitive TORS and selective neck dissection. Patients must sign an informed consent document that indicates they are aware of the investigational nature of the treatment in this protocol as well as the potential risks and benefits. Ability to understand and the willingness to provide written informed consent. \--- Exclusion Criteria: Prior external beam radiation therapy to the head and neck. Prior chemotherapy for head and neck cancer. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery (i.e. AJCC 7th Ed. T4b for OPSCC). Presence of distant metastatic disease. Uncontrolled inter-current illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, connective tissue disease or psychiatric illness/social situations that would limit compliance with study requirements. Known history of hypersensitivity to lidocaine or other amide local anesthetics. Pregnant or breastfeeding.
Where it's running
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Ryan Carey, MD — University of Pennsylvania
- Study coordinator: Ryan Carey, MD
- Email: ryan.carey@pennmedicine.upenn.edu
- Phone: 2156622777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Selective dose reduction of neck radiation in HPV-associated oropharyngeal cancer
This trial tests whether lowering radiation doses to certain neck lymph nodes or gross disease areas is safe and can reduce side effects for adults with HPV-related oropharyngeal cancer.
-
Neoadjuvant chemoimmunotherapy with PD-1 blockade to reduce surgery for advanced head and neck cancer
This approach will try a short course of chemotherapy plus the PD-1 drug toripalimab before standard treatment for people with advanced head and neck cancers to shrink tumors and allow less extensive surgery or radiation.
-
Lower radiation therapy combined with standard chemotherapy for HPV-positive throat cancer
This study is testing whether using less radiation therapy along with standard chemotherapy can help people with HPV-positive throat cancer feel better while causing fewer side effects.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Two-photon microscopy on skin biopsies to help diagnose skin lesions
This study tests whether images from two-photon fluorescence microscopy of dermatology biopsies can match the diagnosis determined by standard histology.
-
Targeted dual-imaging helper for head and neck cancer surgery
This study tests whether using two imaging agents during surgery can help doctors see tumors and cancerous lymph nodes in adults with head and neck squamous cell carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.